Company Profile

Hangzhou Jiuvuan Genetic Biopharmaceutical Co., Ltd.( Stock Code: 02566.Hk)is a new high-tech enterprise, specialized in R&D,manufacture and sales of biopharmaceutical and medical device. We focus on four fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology and hematology. The company was founded in December 1993, as one of the earliest gene engineering pharmaceutical enterprises in Zhejiang province as well as in China.In November 2024, Jiuyuan Gene was listed on the Hong Kong Stock Exchange.

Jiuyuan Gene always upholds the concept "Taking gene engineering as orientation, Rendering service to human health , to pursue innovation and to strive for excelence. In October 1996, the company took the lead in successful development and industrialization of a leukocyte promotion medicine named JILIFEN(Filgrastim. rhG-CSF), entered the market monopolized by U.S and Japanese manufacturers and won a praise of "First lniection in China". Over more than twenty years, the company has actively propelled the progress of biopharmaceutical industrialization,gradually developed a series of products including JILIFEN,JIPAILIN,JIJUFEN,YINUOJIA,JIOUTING,GUYOUDAO,JIFUWEI,JITANSU,JIXINFEN,JILIXIN and so on. Among them, the innovative implantable drug-device combination Guyoudao is China's first bone repair material containing rhBMP-2 approved for sale, and the product under development JY29-2 is China's potential first semaglutide biosimilar approved for commercialization.The company currently has more than 1,800 employees, with sales exceeding 1.3 bilion Yuan in 2025, achieving revenue of more than 1 billion for several consecutive years.

Jiuyuan Gene is a key high-tech enterprise of the National Torch Program,a national intellectual property advantage enterprise and a Zhejiang intellectual property demonstration unit. The company has multiple innovation platforms above the provincial level, including a national postdoctoral workstation, an academician workstation, a Zhejiang key enterprise research institute(newly recognized in 2022), a Zhejiang high-tech R&D center, a Zhejiang enterprise technology center, a Zhejiang key innovation team, etc. The company has been rated as one of the "Top Ten High-tech Enterprises" in Hangzhou twice.

The company's R&D center currently has more than 120 R&D personnel, of which more than 61% are masters and doctors. The core researchers come from well-known domestic universities such as Peking University, Zhejiang University, Nanjing University, and China Pharmaceutical University etc. The research team has rich experience in project establishment,new drug discovery,pilot development, intellectual property rights, and clinical research. We have participated in many national or provincial research projects, have undertaken three major national science and technology projects, and have won a total of 11 national honors for our marketed products. After 30 years of R&D efforts, we have established six product development platforms, enabling us to continuously develop and advance pipeline products.

The company exerts open and aggressive spirit, accumulates numerous resources, absorbs worldwide quintessence, Strive to create a product structure dominated by scientific research and development and technological innovation, mainly to develop biological products, and develop high-end chemical products and innovative drugs as a supplement. Strive to support innovative pharmaceutical industrial enterprises with a relatively complete national market network that focuses on both the basic level market and the central city market.